A hypertrophic cardiomyopathy or transthyretin amyloid cardiomyopathy-like phenotype in the highest (vs lowest) respective quintile conferred a 17% (adjusted hazard ratio 1·17, 95% CI 1·06–1·29; p=0·0022 for hypertrophic cardiomyopathy) and 32% higher adjusted risk of mortality (1·32, 95% CI 1·19–1·46]; p<0·0001 for transthyretin amyloid cardiomyopathy), respectively (figure 5, appendix p 17). This evidence concerns the gene TTR and hypertrophic cardiomyopathy.